X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action. It inhibits the signaling of IL-23, IL-12 and Type 1 IFN, key cytokines involved in the pathogenesis of moderate-to-severe plaque psoriasis.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: Sotyktu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action. It inhibits the signaling of IL-23, IL-12 and Type 1 IFN, key cytokines involved in the pathogenesis of multiple immune-mediated diseases.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: Sotyktu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Sotyktu (deucravacitinib) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action. It inhibits the signaling of IL-23, IL-12 and Type 1 IFN, key cytokines involved in the pathogenesis of multiple immune-mediated diseases.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: Sotyktu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu (deucravacitinib), a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: Sotyktu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Approval is based on results from pivotal Phase 3 trials, which demonstrated superior efficacy of once-daily Sotyktu (deucravacitinib) compared to placebo and twice-daily Otezla® (apremilast) in 1,684 patients aged 18 years and older with moderate-to-severe plaque psoriasis.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: Sotyktu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
BMS-986165 (Deucravacitinib), showed statistically significant efficacy at primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI(4)) responses versus placebo at Week 32.
Lead Product(s): Deucravacitinib
Therapeutic Area: Immunology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with BMS-986165 (deucravacitinib) treatment in adult patients with moderate to severe plaque psoriasis.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
Deucravacitinib is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.
Lead Product(s): Deucravacitinib
Therapeutic Area: Gastroenterology Product Name: BMS-986165
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases.
Lead Product(s): Deucravacitinib
Therapeutic Area: Immunology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
Significantly more patients treated with deucravacitinib achieved PASI 75 and sPGA 0/1 compared to patients treated with placebo and Otezla at Week 16, with an increased benefit versus Otezla at Week 24 and maintained through Week 52.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
POETYK PSO-2 evaluated deucravacitinib 6 mg once daily and met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints.
Lead Product(s): Deucravacitinib
Therapeutic Area: Immunology Product Name: BMS-986165
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Research will be shared on three BMS's assets including: Late-breaking data from a Phase 2 trial of deucravacitinib in patients with active psoriatic arthritis; Orencia program and findings from a Phase 2b trial in patients with active SLE assessing iberdomide.
Lead Product(s): Deucravacitinib
Therapeutic Area: Immunology Product Name: BMS-986165
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints.
Lead Product(s): Deucravacitinib
Therapeutic Area: Dermatology Product Name: BMS-986165
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
